Track record Michael Thiess:

Investment advice – Elaboration and successful implementation of investment strategies

  • Screening of various Venture Capital Life Science funds
  • Investment recommendations for Venture Capital Life Science funds

Business Development – Partnering and portfolio optimization

  • Licensing partner search for an immunomodulatory molecule in phase I/II
  • Portfolio optimization for an oncology company
  • Portfolio optimization for an intensive care company

Venture Support – Company strategy and financing

  • Optimization of the business plan and VC-financing for a medtech company

M&A-Support – Identification and addressing of target candidates

  • Optimization of the product and customer portfolio of an IT company in the healthcare sector
  • Market entry strategy for Europe for a middle-sized Chinese pharmaceutical company

 

Track record Dr. Michael Thiel:

Investment advice – Elaboration and implementation of investment strategies

  • Screening of various Venture Capital Life Science funds
  • Investment recommendations for Venture Capital Life Science funds

Business Development – Partnering and portfolio optimization

  • Market entry of the blockbuster product Olmetec (Olmesartan/hypertonia) in Europe
  • Life cycle management for Olmesartan (introduction of fix combinations, new indications)
  • Early entry strategy for Pravastatin (CSE inhibitor ) in Europe
  • Partner search (Co-Development) for new immunomodulator for phase I/II
  • Portfolio optimization for an intensive care company

M&A-Support – Identification and addressing of target candidates

  • Licensing/acquisition deals in the magnitude of more than 1 bill. $, e.g. Olmesartan partnering in Europe with Menarini, Pfizer